Mainz Biomed N.V. - רווח נקי למניה (EPS TTM) MYNZ

Mainz Biomed N.V. (MYNZ) revenues are based on the implementation of ColoAlert analysis for the detection of colorectal tumors. The annual volatility of net income per share TTM visualizes market expectations, where 12.00 serves as the current metric level. High costs associated with the thermal transportation of biomaterials impact margins. However, the expansion of laboratories in the US and Europe confirms the growth potential of preventive diagnostics.
Mainz Biomed NV - פילוחים אנליטיים ומדדי מפתח (MYNZ)

For Mainz Biomed N.V. (MYNZ), the EPS YoY (TTM) percentage growth history reflects the earnings per share dynamics over a rolling year. This metric measures the rate of change in net income, allowing for an assessment of the business's actual scaling pace. The high sensitivity of this metric reveals the risks of overpaying for the asset when buying at the peak of a trend. For this company, the indicator's volatility depends directly on costly FDA certification processes. Stable EPS growth will confirm the successful navigation of competition within the oncology diagnostics sector.